These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Axonal protection in multiple sclerosis--a particular need during remyelination? Smith KJ Brain; 2006 Dec; 129(Pt 12):3147-9. PubMed ID: 17132643 [No Abstract] [Full Text] [Related]
27. Clinicopathological correlations in multiple sclerosis and related diseases. Waxman SG Adv Neurol; 1981; 31():169-82. PubMed ID: 7325041 [No Abstract] [Full Text] [Related]
28. Cellular immunity in multiple sclerosis. Implications for pathogenesis and treatment. Thompson RF; Davenport J Mo Med; 1984 Oct; 81(10):669-73. PubMed ID: 6092887 [No Abstract] [Full Text] [Related]
29. Multiple sclerosis: re-expression of a developmental gene in chronic lesions correlates with remyelination. Capello E; Voskuhl RR; McFarland HF; Raine CS Ann Neurol; 1997 Jun; 41(6):797-805. PubMed ID: 9189041 [TBL] [Abstract][Full Text] [Related]
30. The riddles of the myelin sheath. Ross T Nurs Mirror; 1982 Sep; 155(13):63-4. PubMed ID: 6923353 [No Abstract] [Full Text] [Related]
31. [The immunology of multiple sclerosis: changing concepts]. Vermersch P Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F138-46. PubMed ID: 18680832 [No Abstract] [Full Text] [Related]
32. Spreading of autoimmunity from central to peripheral myelin: two cases of clinical association between multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. Falcone M; Scalise A; Minisci C; Romito D; Cancelli I; Gigli GL Neurol Sci; 2006 Apr; 27(1):58-62. PubMed ID: 16688601 [TBL] [Abstract][Full Text] [Related]
33. Evidence for pathogenic heterogeneity in multiple sclerosis. Lucchinetti CF; Bruck W; Lassmann H Ann Neurol; 2004 Aug; 56(2):308. PubMed ID: 15293289 [No Abstract] [Full Text] [Related]
34. Multiple sclerosis: remyelination of nascent lesions. Prineas JW; Barnard RO; Kwon EE; Sharer LR; Cho ES Ann Neurol; 1993 Feb; 33(2):137-51. PubMed ID: 8434875 [TBL] [Abstract][Full Text] [Related]
35. [Recent notions concerning the treatments used in multiple sclerosis (author's transl)]. Gonsette RE J Belge Med Phys Rehabil; 1978; 1(3):213-6. PubMed ID: 231031 [No Abstract] [Full Text] [Related]
36. [Comparative neuropathology of multiple sclerosis in Japan and the United States]. Shirabe T Rinsho Shinkeigaku; 1984 Dec; 24(12):1214-6. PubMed ID: 6535673 [No Abstract] [Full Text] [Related]
37. Influence of genetic factors on cell-mediated and humoral immunity in multiple sclerosis. Bernard CC Isr J Med Sci; 1989 Dec; 25(12):682-5. PubMed ID: 2693399 [No Abstract] [Full Text] [Related]
38. Spinal and cranial hypertrophic neuropathy in multiple sclerosis. Quan D; Pelak V; Tanabe J; Durairaj V; Kleinschmidt-Demasters BK Muscle Nerve; 2005 Jun; 31(6):772-9. PubMed ID: 15793846 [TBL] [Abstract][Full Text] [Related]
39. Spontaneous and induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Miller DJ; Rodriguez M Microsc Res Tech; 1995 Oct; 32(3):230-45. PubMed ID: 8527857 [TBL] [Abstract][Full Text] [Related]
40. Experimental strategies to promote central nervous system remyelination in multiple sclerosis: insights gained from the Theiler's virus model system. Miller DJ; Asakura K; Rodriguez M J Neurosci Res; 1995 Jun; 41(3):291-6. PubMed ID: 7563222 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]